| Year |
Citation |
Score |
| 2019 |
Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma. The Oncologist. PMID 30808814 DOI: 10.1634/Theoncologist.2018-0019 |
0.372 |
|
| 2019 |
Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. The Oncologist. PMID 30796156 DOI: 10.1634/Theoncologist.2018-0018 |
0.385 |
|
| 2019 |
Satram-Hoang S, Bajaj P, Stein A, Cortazar P, Momin F, Reyes C. Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data Journal of Cancer Therapy. 10: 117-133. DOI: 10.4236/Jct.2019.102009 |
0.408 |
|
| 2019 |
Satram-Hoang S, Stein A, Cortazar P, Momin F, Reyes C. Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy Journal of Cancer Therapy. 10: 1-20. DOI: 10.4236/Jct.2019.101001 |
0.375 |
|
| 2018 |
Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of Medical Economics. 1-18. PMID 29898619 DOI: 10.1080/13696998.2018.1489254 |
0.335 |
|
| 2018 |
Reyes C, Gauthier G, Shi S, Guerin A. Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia Journal of Cancer Therapy. 9: 576-587. DOI: 10.4236/Jct.2018.97049 |
0.433 |
|
| 2018 |
Burudpakdee C, Seetasith A, Reyes CM, Ogale S, Munakata J, Chu LK. What are the drivers of healthcare cost among patients with metastatic breast cancer (mBC)? Total cost of care analysis to inform value-based reimbursement. Journal of Clinical Oncology. 36: 1092-1092. DOI: 10.1200/Jco.2018.36.15_Suppl.1092 |
0.383 |
|
| 2017 |
Mansfield C, Masaquel A, Sutphin J, Weiss E, Gutierrez M, Wilson J, Boeri M, Li J, Reyes C. Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Advances. 1: 2176-2185. PMID 29296865 DOI: 10.1182/Bloodadvances.2017007294 |
0.41 |
|
| 2017 |
Stokes M, Reyes C, Xia Y, Alas V, Goertz HP, Boulanger L. Impact of pharmacy channel on adherence to oral oncolytics. Bmc Health Services Research. 17: 414. PMID 28629454 DOI: 10.1186/S12913-017-2373-2 |
0.304 |
|
| 2017 |
Matasar MJ, Byfield SD, Blauer-Peterson C, Montez M, Reyes C, Masaquel A. What are the health care costs for chronic lymphocytic leukemia Journal of Clinical Oncology. 35: 15-15. DOI: 10.1200/Jco.2017.35.8_Suppl.15 |
0.391 |
|
| 2017 |
Satram-Hoang S, Reyes CM, Stein A, Hoang KQ, Momin F, Cortazar P. Which patient characteristics drive treatment decisions in elderly patients with early stage hormone receptor–positive breast cancer? Journal of Clinical Oncology. 35: 538-538. DOI: 10.1200/Jco.2017.35.15_Suppl.538 |
0.354 |
|
| 2017 |
Fisher MD, Wallick C, Miller PJ, Walker MS, Lash S, Dawson KL, Reyes CM. How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden Blood. 130: 5666-5666. DOI: 10.1182/Blood.V130.Suppl_1.5666.5666 |
0.372 |
|
| 2017 |
Guzauskas GF, Masaquel A, Thuresson P, Li J, Reyes CM, Veenstra D. Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US? Blood. 130: 5603-5603. DOI: 10.1182/Blood.V130.Suppl_1.5603.5603 |
0.382 |
|
| 2017 |
Satram-Hoang S, Bajaj P, Stein A, Hoang KQ, Momin F, Cortazar P, Reyes C. 277PReal-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx365.040 |
0.323 |
|
| 2017 |
Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Stein A, Kurian A, Cortazar P. 268PWhat are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice? Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx365.031 |
0.339 |
|
| 2016 |
Byfield SD, Bancroft T, Anderson AJ, Reyes CM, Ravelo A, Ogale S, Matasar MJ, Chen MC. Understanding disease progression and treatment patterns in metastatic breast, colorectal, and lung cancer: Implications for evaluating value and quality of care. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 24. PMID 28152674 DOI: 10.1200/Jco.2016.34.7_Suppl.24 |
0.353 |
|
| 2016 |
Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. Medical Care. PMID 26759977 DOI: 10.1097/Mlr.0000000000000486 |
0.314 |
|
| 2016 |
Lalla D, Tevaarwerk A, Goertz H, Smith ML, Bajaj PS, Railey E, Reyes C. What is the health-related quality of life for women with metastatic breast cancer? Journal of Clinical Oncology. 34: 70-70. DOI: 10.1200/Jco.2016.34.7_Suppl.70 |
0.311 |
|
| 2016 |
Engel-Nitz N, Dacosta Byfield S, Bancroft T, Amy AJ, Reyes C, Chen M, Matasar MJ. What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)? Blood. 128: 5957-5957. DOI: 10.1182/Blood.V128.22.5957.5957 |
0.384 |
|
| 2016 |
Matasar MJ, Byfield SD, Blauer-Peterson C, Montez M, Reyes C, Masaquel A. Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States Blood. 128: 5928-5928. DOI: 10.1182/Blood.V128.22.5928.5928 |
0.444 |
|
| 2016 |
Guzauskas GF, Masaquel A, Reyes C, Wilhelm K, Krivasi T, Veenstra DL. What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US? Blood. 128: 3605-3605. DOI: 10.1182/Blood.V128.22.3605.3605 |
0.362 |
|
| 2016 |
Mansfield C, Masaquel A, Sutphin J, Weiss ES, Gutierrez ME, Wilson J, Li J, Reyes C. What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments Blood. 128: 1239-1239. DOI: 10.1182/Blood.V128.22.1239.1239 |
0.407 |
|
| 2015 |
Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guérin A, Yim YM. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Cancer Medicine. PMID 25991583 DOI: 10.1002/Cam4.475 |
0.371 |
|
| 2015 |
Chang CL, Schabert VF, Munakata J, Donga P, Abhyankar S, Reyes CM, Yim YM. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Research. 25: 312-20. PMID 25882026 DOI: 10.1097/Cmr.0000000000000159 |
0.398 |
|
| 2015 |
Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Annals of Hematology. 94: 1127-38. PMID 25791241 DOI: 10.1007/S00277-015-2351-X |
0.419 |
|
| 2015 |
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology (Amsterdam, Netherlands). 20: 129-36. PMID 25029908 DOI: 10.1179/1607845414Y.0000000179 |
0.344 |
|
| 2014 |
Gibney G, Gauthier G, Ayas C, Galebach P, Wu E, Yim YM, Abhyankar SS, Reyes C, Guerin A. 1104PPREDICTORS OF TREATMENT (TX) RESPONSE AND PROGRESSION IN BRAF V600E METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH BRAIN METASTASES (BM) RECEIVING VEMURAFENIB (VEM) IN A REAL-WORLD SETTING. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv382-iv383. PMID 28171138 DOI: 10.1093/Annonc/Mdu344.20 |
0.309 |
|
| 2014 |
Reyes C, Gazauskas G, Veentra D. 1045PCOST-EFFECTIVENESS OF OBINUTUZUMAB IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv359-iv360. PMID 28171093 DOI: 10.1093/Annonc/Mdu341.9 |
0.394 |
|
| 2014 |
Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. The Oncologist. 19: 1249-57. PMID 25342313 DOI: 10.1634/Theoncologist.2014-0113 |
0.345 |
|
| 2014 |
Satram-Hoang S, Reyes C, Hoang KQ, Momin F, Skettino S. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Annals of Hematology. 93: 1335-44. PMID 24638841 DOI: 10.1007/S00277-014-2048-6 |
0.368 |
|
| 2014 |
Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. International Journal of Dermatology. 53: e499-506. PMID 24602078 DOI: 10.1111/Ijd.12427 |
0.333 |
|
| 2014 |
Mathias SD, Chren MM, Colwell HH, Yim YM, Reyes C, Chen DM, Fosko SW. Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. Jama Dermatology. 150: 169-76. PMID 24285085 DOI: 10.1001/Jamadermatol.2013.5870 |
0.339 |
|
| 2014 |
Byfield SD, Small A, Becker LK, Reyes CM. Differences in Treatment Patterns and Health Care Costs among Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Patients Receiving Rituximab in the Hospital Outpatient Setting versus the Office/Clinic Setting Journal of Cancer Therapy. 2014: 208-216. DOI: 10.4236/Jct.2014.52026 |
0.395 |
|
| 2014 |
Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guérin A. Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Journal of Clinical Oncology. 32: 9035-9035. DOI: 10.1200/Jco.2014.32.15_Suppl.9035 |
0.304 |
|
| 2014 |
Chang C, Yim YM, Munakata J, Donga PZ, Reyes CM, Schabert VF. Comparative health care (HC) costs in patients (pts) with metastatic melanoma (mM). Journal of Clinical Oncology. 32: 9007-9007. DOI: 10.1200/Jco.2014.32.15_Suppl.9007 |
0.367 |
|
| 2014 |
Veenstra DL, Reyes CM, Ramsey SD. Is obinutuzumab cost-effective in the first-line treatment of CLL? Journal of Clinical Oncology. 32: 7052-7052. DOI: 10.1200/Jco.2014.32.15_Suppl.7052 |
0.388 |
|
| 2014 |
Satram-Hoang S, Reyes C, Hoang KQ, Momin F, Hurst D, Medeiros BC. Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients Blood. 124: 3698-3698. DOI: 10.1182/Blood.V124.21.3698.3698 |
0.418 |
|
| 2014 |
Medeiros BC, Satram-Hoang S, Hoang KQ, Momin F, Hurst D, Reyes C. Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States Blood. 124: 2272-2272. DOI: 10.1182/Blood.V124.21.2272.2272 |
0.396 |
|
| 2014 |
Medeiros BC, Satram-Hoang S, Hoang KQ, Momin F, Hurst D, Reyes C. Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Blood. 124: 2271-2271. DOI: 10.1182/Blood.V124.21.2271.2271 |
0.407 |
|
| 2014 |
Reyes C, Gazauskas G, Becker U, Moreno S, Veenstra DL. Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Blood. 124: 1324-1324. DOI: 10.1182/Blood.V124.21.1324.1324 |
0.359 |
|
| 2013 |
Dacosta Byfield S, Chen D, Yim YM, Reyes C. Age distribution of patients with advanced non-melanoma skin cancer in the United States. Archives of Dermatological Research. 305: 845-50. PMID 23604961 DOI: 10.1007/S00403-013-1357-2 |
0.35 |
|
| 2013 |
Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Research. 23: 159-66. PMID 23370422 DOI: 10.1097/Cmr.0B013E32835E58D6 |
0.407 |
|
| 2013 |
Satram-Hoang S, Lee L, Yu S, Guduru SR, Gunuganti AR, Reyes C, McKenna E. Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. Journal of Gastrointestinal Cancer. 44: 79-88. PMID 23132351 DOI: 10.1200/Jco.2012.30.4_Suppl.463 |
0.398 |
|
| 2013 |
Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 42: 32-6. PMID 22699203 DOI: 10.1097/Mpa.0B013E318254F19A |
0.338 |
|
| 2013 |
Satram-Hoang S, Lee L, Yu S, Momin F, Guduru SR, Reyes C, McKenna E. Comparative Effectiveness of Adjuvant Chemotherapy in Elderly Colon Cancer Patients Cancer and Clinical Oncology. 2: 115. DOI: 10.5539/Cco.V2N1P115 |
0.399 |
|
| 2013 |
Satram-Hoang S, Reyes C, Hoang KQ, Momin F, Skettino S. The Unmet Need in Chronic Lymphocytic Leukemia: Impact of Comorbidity Burden on Treatment Patterns and Outcomes in Elderly Patients Journal of Cancer Therapy. 4: 1321-1329. DOI: 10.4236/Jct.2013.48156 |
0.412 |
|
| 2013 |
Walker MS, Schwartzberg LS, Chen DM, Ramanan DD, Houts AC, Reyes C. Treatment Patterns and Clinical Characteristics of Patients with Advanced Basal Cell Carcinoma in the Community Oncology Setting Journal of Cancer Therapy. 4: 24-31. DOI: 10.4236/Jct.2013.46A1004 |
0.346 |
|
| 2013 |
Reyes C, Dai M, Goertz H, Dawson KL, Hornberger JC. Does faster rituximab infusion for patients with NHL lower cancer care costs Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E17561 |
0.389 |
|
| 2013 |
Satram-Hoang S, Reyes CM, Hoang K, Momin F, Guduru S, Skettino SL. Which treatment options impact outcomes in elderly chronic lymphocytic leukemia patients with high prevalence of comorbidity Journal of Clinical Oncology. 31: 7016-7016. DOI: 10.1200/Jco.2013.31.15_Suppl.7016 |
0.351 |
|
| 2013 |
Gleeson M, Halperin M, Skettino S, Reyes C. How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013 Blood. 122: 2937-2937. DOI: 10.1182/Blood.V122.21.2937.2937 |
0.386 |
|
| 2013 |
Reyes C, Byfield SD, Becker LK, Small A. Differences In Treatment Patterns and Costs Among Diffuse Large B-Cell Lymphoma Patients Treated In The Clinic Vs. The Hospital Outpatient Setting Blood. 122: 1751-1751. DOI: 10.1182/Blood.V122.21.1751.1751 |
0.446 |
|
| 2012 |
Satram-Hoang S, Ramanan D, Lee LF, Yu S, Reyes CM, McKenna E. Comparative effectiveness of treatment options in elderly patients with colon cancer receiving adjuvant chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 470. PMID 27983128 DOI: 10.1200/Jco.2012.30.4_Suppl.470 |
0.378 |
|
| 2012 |
Raborn ML, Pelletier EM, Smith DB, Reyes CM. Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. Journal of Oncology Practice / American Society of Clinical Oncology. 8: 9s-15s. PMID 22942827 DOI: 10.1200/Jop.2011.000516 |
0.382 |
|
| 2012 |
Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leukemia & Lymphoma. 53: 2371-7. PMID 22591119 DOI: 10.3109/10428194.2012.694429 |
0.401 |
|
| 2012 |
Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 212-8. PMID 22124474 DOI: 10.1097/Jto.0B013E3182307F33 |
0.336 |
|
| 2012 |
Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, Gutierrez H, Satram-Hoang S, Keating MJ. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 225-34. PMID 21824050 DOI: 10.3109/10428194.2011.605918 |
0.371 |
|
| 2012 |
Goulart BHL, Fedorenko CR, Mummy DG, Blough DK, Koepl L, Satram-Hoang S, Reyes CM, Ramsey SD. Who gets a referral to oncologists and subsequent treatments for stages III and IV non-small cell lung cancer (NSCLC)? Journal of Clinical Oncology. 30: 6007-6007. DOI: 10.1200/Jco.2012.30.15_Suppl.6007 |
0.313 |
|
| 2012 |
Satram-Hoang S, Reyes C, Hoang K, Momin F, Guduru SR, Skettino S. Which Patient Characteristics Impact Treatment Choice in Elderly Patients with Chronic Lymphocytic Leukemia Blood. 120: 967-967. DOI: 10.1182/Blood.V120.21.967.967 |
0.418 |
|
| 2012 |
Reyes C, Satram-Hoang S, Hoang K, Momin F, Guduru SR, Skettino S. What Is the Impact of Comorbidity Burden On Treatment Patterns and Outcomes in Elderly Chronic Lymphocytic Leukemia Patients Blood. 120: 758-758. DOI: 10.1182/Blood.V120.21.758.758 |
0.414 |
|
| 2012 |
Byfield SD, Reyes C, Becker LK, Small A. Are There Differences in Patient Characteristics, Treatment Patterns and Costs by Treatment Setting? Blood. 120: 4259-4259. DOI: 10.1182/Blood.V120.21.4259.4259 |
0.424 |
|
| 2012 |
Satram-Hoang S, Skettino S, Hoang K, Guduru SR, Gunuganti A, Reyes C. The Under-Treatment of Elderly Medicare Diffuse Large B-Cell Lymphoma Patients Blood. 120: 237-237. DOI: 10.1182/Blood.V120.21.237.237 |
0.42 |
|
| 2012 |
Hornberger J, Dai M, Goertz H, Dawson KL, Reyes C. Does Faster Rituximab Infusion for Patients with NHL Lower Cancer Care Costs Blood. 120: 2063-2063. DOI: 10.1182/Blood.V120.21.2063.2063 |
0.419 |
|
| 2012 |
Reyes C, Byfield SD, Small A. Are There Differences in Patient Characteristics and Treatment Patterns by Treatment Setting Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33932-6 |
0.391 |
|
| 2011 |
Hornberger JC, Friedmann M, Han L, Chien R, Hornberger RJ, Satram-Hoang S, Reyes C. Economic impact of rituximab as maintenance therapy in previously untreated follicular non-Hodgkin lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18544. PMID 28022961 DOI: 10.1200/Jco.2011.29.15_Suppl.E18544 |
0.338 |
|
| 2011 |
Raborn ML, Pelletier EM, Smith DB, Reyes CM. Are out-of-pocket payments for oral oncologic therapies too high? Updated results from a U.S. claims data analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e16512. PMID 28022271 DOI: 10.1200/Jco.2011.29.15_Suppl.E16512 |
0.331 |
|
| 2011 |
Reyes C, DaCosta Byfield S, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma (mM): Treatment patterns, healthcare use, and costs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8565. PMID 28021045 DOI: 10.1200/Jco.2011.29.15_Suppl.8565 |
0.375 |
|
| 2011 |
Stepanski EJ, Reyes CM, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Schwartzberg LS. Association of skin rash severity and overall survival in patients receiving erlotinib for pancreatic cancer in the community setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14508. PMID 28020638 DOI: 10.1200/Jco.2011.29.15_Suppl.E14508 |
0.342 |
|
| 2011 |
Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS. Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation. Therapeutic Advances in Hematology. 2: 129-39. PMID 23556084 DOI: 10.1177/2040620711407675 |
0.368 |
|
| 2011 |
Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leukemia & Lymphoma. 52: 2117-23. PMID 21745172 DOI: 10.3109/10428194.2011.592623 |
0.358 |
|
| 2011 |
Danese MD, Griffiths RI, Gleeson M, Satram-Hoang S, Knopf K, Mikhael J, Reyes C. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 117: 3505-13. PMID 21190994 DOI: 10.1182/Blood-2010-08-301929 |
0.401 |
|
| 2011 |
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Lopez-Guillermo A, Offner FC, Trneny M, Salles GA. Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma, Blood. 118: 3661-3661. DOI: 10.1182/Blood.V118.21.3661.3661 |
0.331 |
|
| 2011 |
Satram-Hoang S, Reyes C. Is There a Difference in Treatment Patterns Among Follicular Lymphoma Patients Receiving Care in the Outpatient Hospital Versus the Community Clinic Setting Blood. 118: 3134-3134. DOI: 10.1182/Blood.V118.21.3134.3134 |
0.383 |
|
| 2010 |
Griffiths R, Gleeson M, Reyes C, Knopf K, Danese M. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. American Journal of Hematology. 85: 963-7. PMID 20981680 DOI: 10.1002/Ajh.21878 |
0.367 |
|
| 2010 |
Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. Journal of Health Economics. 29: 333-46. PMID 20363520 DOI: 10.1016/J.Jhealeco.2010.02.006 |
0.353 |
|
| 2010 |
Sun E, Jena AB, Lakdawalla D, Reyes C, Philipson TJ, Goldman D. The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 Forum For Health Economics & Policy. 13. DOI: 10.2202/1558-9544.1195 |
0.328 |
|
| 2010 |
Hornberger JC, Reyes CM, Shewade A, Friedmann M, Chan L, Gutierrez H, Satram-Hoang S, Lerner S, Keating MJ. Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 28: e16500-e16500. DOI: 10.1200/Jco.2010.28.15_Suppl.E16500 |
0.358 |
|
| 2010 |
Danese M, Griffiths R, Gleeson M, Satram-Hoang S, Knopf KB, Mikhael J, Reyes CM. Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients. Journal of Clinical Oncology. 28: 6565-6565. DOI: 10.1200/Jco.2010.28.15_Suppl.6565 |
0.384 |
|
| 2010 |
Gruschkus S, Reyes C, Forsyth M, Ravelo A, Nadler E. Pcn41 Economic Outcomes Among 2Nd Line Non-Small Cell Lung Cancer Patients In The Outpatient Community Setting Value in Health. 13. DOI: 10.1016/S1098-3015(11)71937-4 |
0.307 |
|
| 2009 |
Stepanski EJ, Houts AC, Schwartzberg LS, Walker MS, Reyes CM, Blakely J. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clinical Lung Cancer. 10: 426-32. PMID 19900861 DOI: 10.3816/Clc.2009.N.080 |
0.348 |
|
| 2009 |
Gruschkus SK, Darragh JM, Kolodziej MA, Beveridge RA, Forsyth M, Reyes C. Impact of Disease Progression On Healthcare Cost and Resource Utilization Among Follicular NHL Patients Treated within the US Oncology Network. Blood. 114: 4543-4543. DOI: 10.1182/Blood.V114.22.4543.4543 |
0.419 |
|
| 2009 |
Griffiths R, Reyes C, Gleeson M, Knopf K, Danese M. Patterns and Outcomes of Infused Therapy for Chronic Lymphocytic Leukemia (CLL) in a Medicare Population. Blood. 114: 4409-4409. DOI: 10.1182/Blood.V114.22.4409.4409 |
0.394 |
|
| 2009 |
Walker M, Stepanski E, Reyes C, Hasan M, Schwartzberg LS. Symptom Burden in Patients with Follicular Lymphoma Undergoing Maintenance Treatment with Rituxan Compared with Observation. Blood. 114: 2498-2498. DOI: 10.1182/Blood.V114.22.2498.2498 |
0.342 |
|
| 2008 |
Sun E, Lakdawalla D, Reyes C, Goldman D, Philipson T, Jena A. The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6616. PMID 27949685 DOI: 10.1200/Jco.2008.26.15_Suppl.6616 |
0.33 |
|
| 2008 |
Blakely LJ, Schwartzberg LS, Stepanski EJ, Reyes C, Kapur D, Cobb PW, Schnell FM, Walker MS. Practice pattern for patients receiving secondline treatment for non-small cell lung cancer (NSCLC) with erlotinib in the community setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 19102. PMID 27947552 DOI: 10.1200/Jco.2008.26.15_Suppl.19102 |
0.346 |
|
| 2008 |
Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'Connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer Clinical Therapeutics. 30: 775-784. PMID 18498925 DOI: 10.1016/J.Clinthera.2008.04.016 |
0.42 |
|
| 2008 |
Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer. 61: 405-415. PMID 18295368 DOI: 10.1016/J.Lungcan.2007.12.023 |
0.417 |
|
| 2008 |
Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma Leukemia and Lymphoma. 49: 227-236. PMID 18231908 DOI: 10.1080/10428190701769665 |
0.396 |
|
| 2008 |
Danese M, Gleeson M, Reyes C, Pao M, Knopf KB. Cost of chronic lymphocytic leukemia (CLL) in Medicare patients Journal of Clinical Oncology. 26: 17531-17531. DOI: 10.1200/Jco.2008.26.15_Suppl.17531 |
0.415 |
|
| 2007 |
Hornberger J, Reyes C, Verhulst E, Lubeck D, Valente N. Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma Journal of Clinical Oncology. 25: 6583-6583. DOI: 10.1200/Jco.2007.25.18_Suppl.6583 |
0.371 |
|
| 2007 |
Hornberger JC, Reyes C, Shewade A, Loecke D, Valente N. Cost-Effectiveness of Rituximab Post CVP Induction for the Treatment of Low-Grade NHL. Blood. 110: 4486-4486. DOI: 10.1182/Blood.V110.11.4486.4486 |
0.411 |
|
| 2007 |
Ramsey S, Martins R, Blough D, Tock L, Reyes C, Lubeck D. Pcn26 First-, Second- And Third-Line Chemotherapy For Nonsmall Cell Lung Cancer: Patterns Of Care And Cost Value in Health. 10. DOI: 10.1016/S1098-3015(10)68937-1 |
0.321 |
|
| 2006 |
Mathias SD, Cimms TA, Colwell HH, Reyes CM, Lubeck DP. Health-Related Quality of Life of Patients Diagnosed with Indolent Lymphoma. Blood. 108: 5524-5524. DOI: 10.1182/Blood.V108.11.5524.5524 |
0.348 |
|
| 2005 |
Pelletier EM, Hernandez J, Clark MA, Lahue BJ, Reyes CM, Morady F. Medicare costs and health resource utilisation associated with atrial fibrillation in the elderly Journal of Medical Economics. 8: 55-65. DOI: 10.3111/200508055065 |
0.349 |
|
| 2005 |
Pelletier E, Reyes C, Hernandez J, Lee B. Pcv7 Health Care Resource Utilization And Cost Of Atrial Flutter Patients Value in Health. 8: 262-263. DOI: 10.1016/S1098-3015(10)62648-4 |
0.317 |
|
| 2005 |
Reyes C, Hernandez J, Pelletier E, Lee B. Cs4 Cost-Utility Of Catheterablation For First-Line Treatment Of Atrial Flutter Value in Health. 8: 249-250. DOI: 10.1016/S1098-3015(10)62608-3 |
0.305 |
|
| 2005 |
Lee BK, Reyes CM, Hernandez J, Pelletier E, Lu Y, Buell H, Feld GK. Catheter ablation is more cost-effective than cardioversion and drug therapy for first-line treatment of atrial flutter Heart Rhythm. 2. DOI: 10.1016/J.Hrthm.2005.02.014 |
0.305 |
|
| 2002 |
Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 40: 439-46. PMID 12200793 DOI: 10.1053/Ajkd.2002.34881 |
0.311 |
|
| 2001 |
Reyes CM, Nifosì R, Frankel AD, Kollman PA. Molecular dynamics and binding specificity analysis of the bovine immunodeficiency virus BIV Tat-TAR complex. Biophysical Journal. 80: 2833-42. PMID 11371457 DOI: 10.1016/S0006-3495(01)76250-9 |
0.46 |
|
| 2001 |
Wang W, Donini O, Reyes CM, Kollman PA. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annual Review of Biophysics and Biomolecular Structure. 30: 211-43. PMID 11340059 DOI: 10.1146/Annurev.Biophys.30.1.211 |
0.481 |
|
| 2000 |
Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Accounts of Chemical Research. 33: 889-97. PMID 11123888 DOI: 10.1021/Ar000033J |
0.692 |
|
| 2000 |
Nifosì R, Reyes CM, Kollman PA. Molecular dynamics studies of the HIV-1 TAR and its complex with argininamide. Nucleic Acids Research. 28: 4944-55. PMID 11121486 DOI: 10.1093/Nar/28.24.4944 |
0.458 |
|
| 2000 |
Reyes CM, Kollman PA. Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. Journal of Molecular Biology. 297: 1145-58. PMID 10764579 DOI: 10.1006/Jmbi.2000.3629 |
0.483 |
|
| 2000 |
Reyes CM, Kollman PA. Investigating the binding specificity of U1A-RNA by computational mutagenesis. Journal of Molecular Biology. 295: 1-6. PMID 10623503 DOI: 10.1006/Jmbi.1999.3319 |
0.456 |
|
| 1999 |
Reyes CM, Kollman PA. Molecular dynamics studies of U1A-RNA complexes. Rna (New York, N.Y.). 5: 235-44. PMID 10024175 DOI: 10.1017/S1355838299981657 |
0.464 |
|
| Show low-probability matches. |